Reserved for actively bleeding patients since acquired inhibitors may not give rise to symptoms. First line treatment is often FFP but large volumes may be required and efficacy may be limited. Some specific concentrates are available. Recombinant VIIa can be considered in many cases. Treatment of the underlying condition may cause the inhibitor to disappear.

Hay, C.R. et ai. (1996) Recommendations for the treatment of factor VIII inhibitors: from the UK Haemophilia Centre Directors' Organisation Inhibitor Working Party. Blood Coagui Fibrinolysis, 7, 134-138.

0 0

Post a comment